Real-World study tracks Brigatinib's performance in chinese lung cancer patients

NCT ID NCT05721950

Ongoing Knowledge-focused Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how long Chinese patients with ALK-positive advanced lung cancer stay on brigatinib treatment in real-world settings. Researchers will also track cancer progression and response to the drug. About 154 participants are included, and the study simply observes their medical records without giving any new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: brigatinib (Alunbrig)
What this could lead to: If successful, this study could confirm that brigatinib is effective and safe for Chinese patients with ALK-positive lung cancer in everyday clinical practice.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by patient differences and real-world factors. It does not test a new treatment, only gathers data on existing use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Locations

Department of Oncology, Shanghai pulmonary hospital

Shanghai, Shanghai Municipality, 200433, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.